Lupus nephritis has historically been treated with broad immunosuppression and steroids, with remission rates that left substantial room for improvement. Lupkynis (voclosporin) arrived as the first FDA-approved oral therapy developed specifically for the condition.
It is a calcineurin inhibitor that reduces the immune-driven kidney inflammation behind proteinuria, while also stabilizing the podocytes that maintain the glomerular filtration barrier. Approved for adults with active lupus nephritis, it is used alongside background immunosuppressive therapy.
Lupkynis remains on the market without generic competition and holds orphan drug designation. As the first oral agent approved in lupus nephritis it is a standard comparator in the space, and worth tracking as competing therapies pursue the same indication.
